BIOTECH ENGINEERING
ActiveSummary
BIOTECH ENGINEERING has been active since 1997 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €418,727 and a net result of €242,696. Equity is shrinking by about 4.4% per year across the filed financial years. Its solvency ranks better than 49% of 11,709 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Directors
Board 2
Permanent representatives 2
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Biotech-Invest |
|
| DDE Group |
|
| AIM |
|
| Heyvaerts,Stefaan Fernand Marie |
|
Owners and capital
Owners
1 ownerChain of control
- BIOTECH-INVEST
- BIOTECH ENGINEERING
Highest known parent: BIOTECH-INVEST. The sources do not say who stands above it.
Owners 1
- BIOTECH-INVESTparent75%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 07-04-2026 Capital stated in the deed · 2,500 shares
- 12-12-2023 Converted to unavailable equity